{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:42:23Z","timestamp":1765827743611},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T00:00:00Z","timestamp":1546819200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12882-018-1196-7","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T06:17:21Z","timestamp":1546928241000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Achievement of renal anemia KDIGO targets by two different clinical strategies \u2013 a European hemodialysis multicenter analysis"],"prefix":"10.1186","volume":"20","author":[{"given":"Maciej","family":"Drozdz","sequence":"first","affiliation":[]},{"given":"Andr\u00e9","family":"Weigert","sequence":"additional","affiliation":[]},{"given":"Fatima","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Fraz\u00e3o","sequence":"additional","affiliation":[]},{"given":"Abdulkareem","family":"Alsuwaida","sequence":"additional","affiliation":[]},{"given":"Mahesh","family":"Krishnan","sequence":"additional","affiliation":[]},{"given":"Werner","family":"Kleophas","sequence":"additional","affiliation":[]},{"given":"Szymon","family":"Brzosko","sequence":"additional","affiliation":[]},{"given":"Fredrik K.","family":"Johansson","sequence":"additional","affiliation":[]},{"given":"Stefan H.","family":"Jacobson","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,1,7]]},"reference":[{"key":"1196_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1053\/j.ajkd.2005.09.007","volume":"47","author":"N Volkova","year":"2006","unstructured":"Volkova N, Arab L. Evidence-based systematic literature review of hemoglobin\/hematocrit and all-cause mortality in dialysis patients. Am J Kidney Dis. 2006;47:24\u201336.","journal-title":"Am J Kidney Dis"},{"key":"1196_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1159\/000366478","volume":"128","author":"F Locatelli","year":"2014","unstructured":"Locatelli F, de Francisco A, Deray G, Fliser D, Armstrong G, Dougherty FC, Ehrhard P. Mortality and cardiovascular morbidity associated with haemoglobin levels: a pooled analysis of randomised controlled trials. Nephron Clin Pract. 2014;128:323\u201332.","journal-title":"Nephron Clin Pract"},{"key":"1196_CR3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJM199808273390903","volume":"339","author":"A Besarab","year":"1998","unstructured":"Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584\u201390.","journal-title":"N Engl J Med"},{"key":"1196_CR4","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa062276","volume":"355","author":"TB Drueke","year":"2006","unstructured":"Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071\u201384.","journal-title":"N Engl J Med"},{"key":"1196_CR5","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","volume":"355","author":"AK Singh","year":"2006","unstructured":"Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085\u201398.","journal-title":"N Engl J Med"},{"key":"1196_CR6","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/ki.2008.295","volume":"74","author":"LA Szczech","year":"2008","unstructured":"Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74:791\u20138.","journal-title":"Kidney Int"},{"key":"1196_CR7","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","volume":"361","author":"MA Pfeffer","year":"2009","unstructured":"Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019\u201332.","journal-title":"N Engl J Med"},{"key":"1196_CR8","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.2215\/CJN.02600315","volume":"10","author":"A Karaboyas","year":"2015","unstructured":"Karaboyas A, Zee J, Morgenstern H, Nolen JG, Hakim R, Kalantar-Zadeh K, Zager P, Pisoni RL, Port FK, Robinson BM. Understanding the recent increase in ferritin levels in United States Dialysis patients: potential impact of changes in intravenous Iron and erythropoiesis-stimulating agent dosing. Clin J Am Soc Nephrol. 2015;10:1814\u201321.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1196_CR9","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/ki.2010.382","volume":"79","author":"T Hasegawa","year":"2011","unstructured":"Hasegawa T, Bragg-Gresham JL, Pisoni RL, Robinson BM, Fukuhara S, Akiba T, Saito A, Kurokawa K, Akizawa T. Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin. Kidney Int. 2011;79:340\u20136.","journal-title":"Kidney Int"},{"key":"1196_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.semnephrol.2006.06.001","volume":"26","author":"M Nangaku","year":"2006","unstructured":"Nangaku M, Eckardt KU. Pathogenesis of renal anemia. Semin Nephrol. 2006;26:261\u20138.","journal-title":"Semin Nephrol"},{"key":"1196_CR11","doi-asserted-by":"publisher","first-page":"c38","DOI":"10.1159\/000228074","volume":"113","author":"S Flint","year":"2009","unstructured":"Flint S, Taylor E, Beavis J, Becker GJ, Pedagogos E. Increased iron requirement in hemodialysis patients on antiplatelet agents or warfarin. Nephron Clin Pract. 2009;113:c38\u201345.","journal-title":"Nephron Clin Pract"},{"key":"1196_CR12","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1681\/ASN.V7122654","volume":"7","author":"S Fishbane","year":"1996","unstructured":"Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK. The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol. 1996;7:2654\u20137.","journal-title":"J Am Soc Nephrol"},{"key":"1196_CR13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/0272-6386(95)90649-5","volume":"26","author":"K Kalantar-Zadeh","year":"1995","unstructured":"Kalantar-Zadeh K, Hoffken B, Wunsch H, Fink H, Kleiner M, Luft FC. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis. 1995;26:292\u20139.","journal-title":"Am J Kidney Dis"},{"key":"1196_CR14","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3324\/haematol.2014.111492","volume":"99","author":"D Rampton","year":"2014","unstructured":"Rampton D, Folkersen J, Fishbane S, Hedenus M, Howaldt S, Locatelli F, Patni S, Szebeni J, Weiss G. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014;99:1671\u20136.","journal-title":"Haematologica"},{"key":"1196_CR15","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1053\/ajkd.2002.36334","volume":"40","author":"D Tovbin","year":"2002","unstructured":"Tovbin D, Mazor D, Vorobiov M, Chaimovitz C, Meyerstein N. Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. Am J Kidney Dis. 2002;40:1005\u201312.","journal-title":"Am J Kidney Dis"},{"key":"1196_CR16","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1053\/j.ajkd.2008.12.035","volume":"53","author":"YK Lee","year":"2009","unstructured":"Lee YK, Koo JR, Kim JK, Park II, Joo MH, Yoon JW, Noh JW, Vaziri ND. Effect of route of EPO administration on hemodialysis arteriovenous vascular access failure: a randomized controlled trial. Am J Kidney Dis. 2009;53:815\u201322.","journal-title":"Am J Kidney Dis"},{"key":"1196_CR17","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1053\/j.ajkd.2008.12.040","volume":"53","author":"K Kalantar-Zadeh","year":"2009","unstructured":"Kalantar-Zadeh K, Lee GH, Miller JE, Streja E, Jing J, Robertson JA, Kovesdy CP. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis. 2009;53:823\u201334.","journal-title":"Am J Kidney Dis"},{"key":"1196_CR18","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1093\/ndt\/gfl716","volume":"22","author":"J Rossert","year":"2007","unstructured":"Rossert J, Gassmann-Mayer C, Frei D, McClellan W. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant. 2007;22:794\u2013800.","journal-title":"Nephrol Dial Transplant"},{"key":"1196_CR19","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/kisup.2012.37","volume":"2","author":"Kidney Disease","year":"2012","unstructured":"Kidney Disease. Improving global outcomes Anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:279\u2013335.","journal-title":"Kidney Int Suppl"},{"key":"1196_CR20","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/08860220701857241","volume":"30","author":"A Wiecek","year":"2008","unstructured":"Wiecek A, Covic A, Locatelli F, Macdougall IC. Renal anemia: comparing current eastern and Western European management practice (ORAMA). Ren Fail. 2008;30:267\u201376.","journal-title":"Ren Fail"},{"key":"1196_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ndt\/14.suppl_4.1a","volume":"14","author":"European survey on anemia management (ESAM)","year":"1999","unstructured":"European survey on anemia management (ESAM). Nephrol Dial Transplant. 1999;14:1\u201376.","journal-title":"Nephrol Dial Transplant"},{"key":"1196_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0272-6386(96)90130-4","volume":"28","author":"RN Foley","year":"1996","unstructured":"Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53\u201361.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1196_CR23","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/ndt\/gfx269","volume":"33","author":"R Perez-Garcia","year":"2017","unstructured":"Perez-Garcia R, Varas J, Cives A, Martin-Malo A, Aljama P, Ramos R, Pascual J, Stuard S, Canaud B, Merello JI. Increased mortality in haemodialysis patients administered high doses of erythropoiesis-stimulating agents: a propensity score-matched analysis. Nephrol Dial Transplant. 2017;33(4):690\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1196_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/ncpneph0655","volume":"4","author":"K Putten van der","year":"2008","unstructured":"van der Putten K, Braam B, Jie KE, Gaillard CA. Mechanisms of disease: erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol. 2008;4:47\u201357.","journal-title":"Nat Clin Pract Nephrol"},{"key":"1196_CR25","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.kint.2016.03.009","volume":"90","author":"D Marcelli","year":"2016","unstructured":"Marcelli D, Bayh I, Merello JI, Ponce P, Heaton A, Kircelli F, Chazot C, Di Benedetto A, Marelli C, Ladanyi E, et al. Dynamics of the erythropoiesis stimulating agent resistance index in incident hemodiafiltration and high-flux hemodialysis patients. Kidney Int. 2016;90:192\u2013202.","journal-title":"Kidney Int"},{"key":"1196_CR26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.23876\/j.krcp.2017.36.3.209","volume":"36","author":"P Biggar","year":"2017","unstructured":"Biggar P, Kim GH. Treatment of renal anemia: erythropoiesis stimulating agents and beyond. Kidney Res Clin Pract. 2017;36:209\u201323.","journal-title":"Kidney Res Clin Pract"},{"key":"1196_CR27","first-page":"173","volume":"32","author":"WM Michels","year":"2017","unstructured":"Michels WM, Jaar BG, Ephraim PL, Liu Y, Miskulin DC, Tangri N, Crews DC, Scialla JJ, Shafi T, Sozio SM, et al. Intravenous iron administration strategies and anemia management in hemodialysis patients. Nephrol Dial Transplant. 2017;32:173\u201381.","journal-title":"Nephrol Dial Transplant"},{"key":"1196_CR28","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2215\/CJN.04280609","volume":"5","author":"S Stancu","year":"2010","unstructured":"Stancu S, Barsan L, Stanciu A, Mircescu G. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? Clin J Am Soc Nephrol. 2010;5:409\u201316.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1196_CR29","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.2215\/CJN.03370414","volume":"9","author":"DC Miskulin","year":"2014","unstructured":"Miskulin DC, Tangri N, Bandeen-Roche K, Zhou J, McDermott A, Meyer KB, Ephraim PL, Michels WM, Jaar BG, Crews DC, et al. Intravenous iron exposure and mortality in patients on hemodialysis. Clin J Am Soc Nephrol. 2014;9:1930\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1196_CR30","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/ndt\/gfu349","volume":"30","author":"N Tangri","year":"2015","unstructured":"Tangri N, Miskulin DC, Zhou J, Bandeen-Roche K, Michels WM, Ephraim PL, McDermott A, Crews DC, Scialla JJ, Sozio SM, et al. Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEcIDE-ESRD study. Nephrol Dial Transplant. 2015;30:667\u201375.","journal-title":"Nephrol Dial Transplant"},{"key":"1196_CR31","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/ndt\/gfx209","volume":"33","author":"J Varas","year":"2018","unstructured":"Varas J, Ramos R, Aljama P, Perez-Garcia R, Moreso F, Pinedo M, Ignacio Merello J, Stuard S, Canaud B, Martin-Malo A. Relationships between iron dose, hospitalizations and mortality in incident haemodialysis patients: a propensity-score matched approach. Nephrol Dial Transplant. 2018;33:160\u201370.","journal-title":"Nephrol Dial Transplant"},{"key":"1196_CR32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2215\/CJN.05390517","volume":"13","author":"I Hougen","year":"2018","unstructured":"Hougen I, Collister D, Bourrier M, Ferguson T, Hochheim L, Komenda P, Rigatto C, Tangri N. Safety of intravenous Iron in Dialysis: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2018;13:457\u201367.","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-1196-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-018-1196-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-1196-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T21:25:15Z","timestamp":1662758715000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-018-1196-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,7]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1196"],"URL":"https:\/\/doi.org\/10.1186\/s12882-018-1196-7","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,7]]},"assertion":[{"value":"13 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the regional Ethics Committee at the Karolinska Institutet, Stockholm, Sweden. This study was a retrospective analysis of statistically deidentified data; informed consent was not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"WK has received speaker fees from Boehringer Ingelheim, Hexal, Profil Deutschland, IAD, Sanofi Aventis, Astra Zeneca, Amgen, and Abbvie. All other authors have no competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"5"}}